![\"\"](\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/01\/image001.png\")
<\/h3>\nThe management of low-density lipoprotein cholesterol (LDL-C) has transitioned into an intensive paradigm emphasizing sustained lowering, often summarized as \u201clower for longer.\u201dCentral to this shift is the therapeutic targeting of proprotein convertase subtilisin\/kexin type 9(PCSK9). While cardiovascular benefits are well-established, concerns regarding neurocognitive safety at extremely low LDL-C levels have persisted. This review synthesizes genetic,mechanistic, and clinical evidence addressing the relationship between PCSK9 modulation,lifelong lipid exposure, and neurodegenerative risk, specifically Alzheimer\u2019s disease (AD).<\/p>\n
<\/h3>\nThe discovery of PCSK9 as a key regulator of LDL receptor (LDLR) density has revolutionized lipidology [1-3]. Monoclonal antibodies and gene-editing techniques targeting PCSK9 allow for LDL-C reductions exceeding 60%, often reaching levels below 20 mg\/dL [15]. Given the high cholesterol content of the brain, the safety of such profound systemic depletion remains acritical area of longitudinal analysis.<\/p>\n
PCSK9 is a serine protease that binds to the epidermal growth factor-like repeat A (EGF-A) domain of the hepatic LDLR [2]. Under physiological conditions, this binding targets the receptor for lysosomal degradation, preventing its recycling to the cell surface and thereby increasing circulating LDL-C. Pharmacological inhibition\u2014via monoclonal antibodies or newer strategies like CRISPR-based base editing\u2014interrupts this interaction, restoring LDLR availability and enhancing LDL clearance from the plasma [3, 18].<\/p>\n
Human genetics provide a \u201cnatural experiment\u201d to assess long-term PCSK9 modulation. Loss-of-function (LoF) variants, such as the R46L variant common in European populations, lead to lifelong lower LDL-C and significant protection against atherosclerotic cardiovascular disease(ASCVD) [4-5]. Importantly, rare individuals with homozygous \u201cnull\u201d phenotypes exhibit LDL-Clevels as low as 15 mg\/dL without overt neurocognitive impairment, suggesting that systemicLDL-C depletion is compatible with normal human physiology [6].<\/p>\n
A critical mechanistic safeguard for neurocognitive health is the isolation of brain cholesterol metabolism. Approximately 25% of the body\u2019s cholesterol is located in the CNS, yet it is functionally separated from systemic pools by the blood\u2013brain barrier (BBB) [10]. Brain cholesterol is synthesized de novo primarily by astrocytes and neurons; it does not depend on circulating LDL-C particles [10]. Furthermore, monoclonal antibodies targeting PCSK9 are largemolecules that do not cross an intact BBB, precluding direct CNS interaction [1].<\/p>\n
Early Mendelian Randomization (MR) studies raised speculative concerns regarding a possible increase in AD risk associated with lower LDL-C [9]. However, subsequent large-scale MR analyses involving over 115,000 individuals and higher-powered meta-analyses effectively refute these signals [9, 17]. Specifically, studies targeting LDL-C-lowering variants in the PCSK9 and HMGCR loci show a neutral odds ratio (OR \u2248 0.97) for AD, and some data suggest potential protective effects when non-HDL cholesterol is lowered over a lifetime [16-17].<\/p>\n
Randomized controlled trials (RCTs) provide the most direct evidence of safety. The EBBINGHAUS study, a prospective neurocognitive substudy of the FOURIER trial, utilized objective cognitive testing in nearly 2,000 patients [11]. Over a median follow-up of 19 months,no differences were observed between evolocumab and placebo. Long-term extension data(FOURIER-OLE) reached follow-up durations of 7+ years, demonstrating sustained cognitivestability even among those achieving LDL-C levels < 20 mg\/dL [12, 15]. Similar safety profileshave been established for alirocumab in the ODYSSEY OUTCOMES trial and subsequent meta-analyses [13].<\/p>\n
The log-linear relationship between LDL-C reduction and ASCVD risk reduction remains consistent across the therapeutic spectrum [14]. Clinical evidence suggests that the benefit of aggressive lowering continues without a plateau, while safety markers for dementia and cognitive decline remain flat [15].<\/p>\n
Comprehensive analysis of genetic epidemiology, mechanistic biology, and randomized clinical trials consistently supports the conclusion that PCSK9 inhibition and extremely low LDL-C do not increase the risk of Alzheimer\u2019s disease or other dementias. Local regulation of CNS cholesterol synthesis and BBB isolation provide a biological basis for systemic lipid management without neurocognitive consequence.<\/p>\n
References<\/strong><\/p>\n Le LDL peut-il \u00eatre trop bas ? Ce que les inhibiteurs de la PCSK9 signifient pour la sant\u00e9 c\u00e9r\u00e9brale<\/p>\n Les inhibiteurs de la PCSK9 comptent parmi les traitements hypolipid\u00e9miants les plus puissants qui soient. Ils permettent de r\u00e9duire le taux de LDL (\u201c mauvais cholest\u00e9rol \u201d) de 50 \u00e0 60%, voire davantage, et peuvent, dans certains cas, faire passer ce taux en dessous de 20 mg\/dL.<\/p>\n C'est un outil extraordinaire pour pr\u00e9venir les crises cardiaques et les accidents vasculaires c\u00e9r\u00e9braux. Mais cela soul\u00e8ve \u00e9galement une question l\u00e9gitime : si le \u201cmauvais\u201d cholest\u00e9rol est n\u00e9cessaire au cerveau, le LDL pourrait-il devenir \"trop bas\" et augmenter le risque de maladie d'Alzheimer ou de d\u00e9mence ?<\/p>","protected":false},"author":16,"featured_media":8586,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[227,219,223,224],"tags":[],"class_list":["post-8531","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-apob-and-lipid-science","category-lipids-medications-and-testing","category-plaque-arteries-and-disease","category-regression-and-reversal"],"acf":[],"yoast_head":"\n\n